$Sutro Biopharma(STRO.US)$Sutro Biopharma Inc (STRO) has provided an announcement. Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
The low P/S ratio of Sutro Biopharma is attributed to its inferior revenue outlook and shareholders' pessimism about the company's future growth. The company's share price is unlikely to rise significantly in the near future due to these circumstances.
The lack of insider transactions in the last three months and low insider ownership in Sutro Biopharma is concerning. Investors should also note the company's 3 warning signs.
$Sutro Biopharma(STRO.US)$Sutro Biopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment) SEC announcement· just
ZZZZakk : nice